insights_auto
为什么 ZYME 上涨了 4.21%?
深入探索chevron_right
ZYME:NASDAQ
Zymeworks Inc
US$26.21
arrow_upward
+4.21%(+1.06) 1 天
US$26.21
0.00% (0.00)
bedtime盘后交易
休市： 10月5日, GMT-4 16:00:01 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ZYME 生成关键数据洞见…
开盘价
US$25.37
最高价
US$26.50
最低价
US$25.28
市值
18.60亿
平均成交量
84.55万
成交量
61.40万
52 周最高价
US$31.34
52 周最低价
US$16.00
每股收益
-US$2.01
Beta 版
1.17
流通股数
7095.90万
员工人数
231
开盘价
US$25.37
最高价
US$26.50
最低价
US$25.28
市值
18.60亿
平均成交量
84.55万
成交量
61.40万
52 周最高价
US$31.34
52 周最低价
US$16.00
每股收益
-US$2.01
Beta 版
1.17
流通股数
7095.90万
员工人数
231
新闻报道
来自网络来源和新闻合作伙伴
AD HOC NEWS
·
2小时前
Zymeworks stock gains 4.85 percent after 2026 outlook update
Stock Traders Daily
·
23小时前
Liquidity Mapping Around (ZYME) Price Events
资料
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Zymeworks Inc简介